This issue of memo inHaematology summarizes key findings from studies presented at ASH 2024, including results from ongoing and recent clinical trials on the use of monotherapies and combination therapies with Bruton’s tyrosine kinase (BTK) and B-cell lymphoma 2 (Bcl2) inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL) and Waldenström’s macroglobulinemia (WM). The report also highlights the potential of innovative targeted therapies, including a bispecific antibody (BsAb) for FL, and BTK degraders for treating CLL/SLL and other B-cell malignancies.